USL261 (Intranasal Midazolam) Data
USL261 data presented at AAN 2013 examined the pharmacokinetics, pharmacodynamics, safety, and tolerability of USL261 in healthy volunteers. In this study, increasing USL261 doses corresponded with an apparent linear increase in midazolam exposure, with all doses demonstrating rapid time to maximal plasma concentration (10 – 15 min). Researchers concluded that USL261 dosed up to 7.5 mg was generally well tolerated and did not result in excessive or prolonged sedation or psychomotor impairment. Further, when compared with an equivalent dose of injectable midazolam delivered intranasally, USL261 demonstrated improved midazolam bioavailability with similar pharmacodynamic effects and safety/tolerability profiles.
Abstracts of the poster presentations can be found online at: http://www.aan.com
Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions. More than two million
|SOURCE Upsher-Smith Laboratories, Inc.|
Copyright©2012 PR Newswire.
All rights reserved